CytoMed Therapeutics Limited (GDTC)

Market Cap	25.51M
Revenue (ttm)	330,254
Net Income (ttm)	-2.26M
Shares Out	11.54M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,541
Open	2.150
Previous Close	2.040
Day's Range	1.880 - 2.350
52-Week Range	1.200 - 5.500
Beta	n/a
Analysts	Buy
Price Target	5.00 (+126.22%)
Earnings Date	n/a

About GDTC

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural kil...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 14, 2023
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: GDTC
• Website: https://w2.cytomed.sg

Financial Performance

In 2023, CytoMed Therapeutics's revenue was 507,736, an increase of 39.52% compared to the previous year's 363,912. Losses were -4.13 million, 32.0% more than in 2022.

Financial numbers in SGD

Analyst Forecast

According to one analyst, the rating for GDTC stock is "Buy" and the 12-month stock price forecast is $5.0.

Price Target

$5.0

(126.22% upside)

Analyst Consensus: Buy